Radiopharm Theranostics Doses First Patient in Phase I ‘HEAT’ Trial of 177lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Radiopharm Theranostics announced the dosing of the first patient in its Phase I ‘HEAT’ clinical trial of RAD202, a proprietary nanobody that targets Human Epidermal Growth Factor Receptor 2 (HER2)-positive expression in a wide array of advanced solid tumors.